Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU
ncarol.com/10292365

MIYUN, China - ncarol.com -- Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) issued by the Netherlands Medicines Evaluation Board (MEB) in accordance with the relevant regulations of the European Medicines Agency.

Certificate information:

• Company name: Beijing Beilu pharmaceutical Co., Ltd.
• Manufacturing address: No.3 Shuiyuan West Road, Miyun District, Beijing, China
• Registration number: RVG 132878
• Drug name: Iohexol injection 350mg(I)/ml
• Issuing authority: Netherlands Medicines Evaluation Board (MEB)

The successful registration of Iohexol Injection in Netherland indicates that the product has undergone rigorous scientific evaluation by EMA, confirming its compliance with EU Good Manufacturing Practice (GMP), quality, safety and efficacy standards. This authorization enables commercial distribution in EU-approved countries. It creates conditions for speeding up the Mutual recognition procedures(MRP) among EU countries such as Germany, France, Italy and others as well. This will help Beilu Pharmaceutical further promote the expansion of its overseas market and enhance the international market competitiveness of its contrast agent products, which is expected to have a positive impact on the company's operations in the future.

More on ncarol.com

• Gigasoft Solves AI's Biggest Charting Code Problem: Hallucinated Property Names
• Akg To Demonstrate New Digital E-catalog Experience Daily At Conexpo-con/agg 2026
• ASTI Ignites the Space Economy: Powering SpaceX's NOVI AI Pathfinder with Breakthrough Solar Technology: Ascent Solar Technologies (N A S D A Q: ASTI)
• STEM For Kids Launches Root Protocol™: A Human Bridge for Gen Alpha's Digital Curiosity Crisis
• Hiring has reached a "Digital Stalemate"—Now, an ex-Google recruiter is giving candidates the answers

Contact Information:
Beijing Beilu Pharmaceutical Co., Ltd.
https://www.beilupharma.com/
yanglm@beilupharma.com